Last updated on October 2017

Tenofovir Alafenamide (TAF) in Adolescents With Chronic Hepatitis B Virus Infection


Brief description of study

The primary objectives of this study are as follows: Part A: To evaluate the steady state pharmacokinetics (PK) of tenofovir alafenamide (TAF) and confirm the dose of TAF 25 mg tablet given once daily in treatment-naive and treatment-experienced adolescents (aged 12 to < 18 years) with chronic hepatitis B (CHB) Part B: To evaluate the safety, tolerability, and antiviral activity (HBV DNA < 20 IU/mL) of TAF 25 mg once daily versus placebo through Week 24 in treatment-naive and treatment-experienced adolescents with CHB.

Clinical Study Identifier: NCT02932150

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Gilead Study Team

San Francisco, CA United States
  Connect »

Gilead Study Team

Miami, FL United States
  Connect »

Gilead Study Team

Indianapolis, IN United States
  Connect »

Gilead Study Team

Baltimore, MD United States
  Connect »

Gilead Study Team

Omaha, NE United States
  Connect »

Gilead Study Team

Fort Worth, TX United States
  Connect »

Gilead Study Team

Houston, TX United States
  Connect »

Gilead Study Team

San Antonio, TX United States
  Connect »

Gilead Study Team

Seattle, WA United States
  Connect »

Gilead Study Team

Morgantown, WV United States
  Connect »

Gilead Study Team

Hong Kong, Hong Kong
  Connect »

Gilead Study Team

Daegu, Korea, Republic of
  Connect »

Gilead Study Team

Seoul, Korea, Republic of
  Connect »

Gilead Study Team

Kazan, Russian Federation
  Connect »

Gilead Study Team

Krasnoyarsk, Russian Federation
  Connect »

Gilead Study Team

Moscow, Russian Federation
  Connect »

Gilead Study Team

Saint Petersburg, Russian Federation
  Connect »

Gilead Study Team

Tolyatti, Russian Federation
  Connect »